Li, Lin <br/><br/>
Telekin suppresses human hepatocellular carcinoma cells in vitro by inducing G2/M phase arrest via the p38 MAPK signaling pathway.  [electronic resource] 

 -  Acta pharmacologica Sinica  Oct 2014 
 - 1311-22 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1745-7254 
<br/><br/><label>Standard No.: </label>10.1038/aps.2014.74  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>CDC2 Protein Kinase<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cell Cycle Checkpoints--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Cyclin B1--metabolism<br/>Cyclin-Dependent Kinases--metabolism<br/>G2 Phase Cell Cycle Checkpoints--drug effects<br/>Hep G2 Cells<br/>Humans<br/>Intracellular Signaling Peptides and Proteins--metabolism<br/>Liver Neoplasms--drug therapy<br/>Protein Serine-Threonine Kinases--metabolism<br/>Reactive Oxygen Species--metabolism<br/>Sesquiterpenes, Eudesmane--pharmacology<br/>Signal Transduction--drug effects<br/>cdc25 Phosphatases--metabolism<br/>p38 Mitogen-Activated Protein Kinases--metabolism